Enliven Therapeutics (ELVN) Competitors

Enliven Therapeutics logo
$46.44 +0.03 (+0.06%)
Closing price 11/20/2026 03:58 PM Eastern
Extended Trading
$46.54 +0.10 (+0.22%)
As of 11/20/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

ELVN vs. SMMT, KYMR, HALO, BMRN, and PCVX

Should you buy Enliven Therapeutics stock or one of its competitors? Enliven Therapeutics's main competitors and comparable companies include Summit Therapeutics (SMMT), Kymera Therapeutics (KYMR), Halozyme Therapeutics (HALO), BioMarin Pharmaceutical (BMRN), and Vaxcyte (PCVX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Enliven Therapeutics compare to Summit Therapeutics?

Enliven Therapeutics (NASDAQ:ELVN) and Summit Therapeutics (NASDAQ:SMMT) are both mid-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, dividends, institutional ownership, profitability, valuation, analyst recommendations, media sentiment and risk.

In the previous week, Summit Therapeutics had 18 more articles in the media than Enliven Therapeutics. MarketBeat recorded 30 mentions for Summit Therapeutics and 12 mentions for Enliven Therapeutics. Enliven Therapeutics' average media sentiment score of 0.82 beat Summit Therapeutics' score of -0.55 indicating that Enliven Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Enliven Therapeutics
2 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Summit Therapeutics
1 Very Positive mention(s)
2 Positive mention(s)
7 Neutral mention(s)
10 Negative mention(s)
6 Very Negative mention(s)
Negative

Enliven Therapeutics has a beta of 0.34, meaning that its share price is 66% less volatile than the broader market. Comparatively, Summit Therapeutics has a beta of -1.49, meaning that its share price is 249% less volatile than the broader market.

Enliven Therapeutics currently has a consensus price target of $75.44, suggesting a potential upside of 62.46%. Summit Therapeutics has a consensus price target of $28.10, suggesting a potential upside of 182.41%. Given Summit Therapeutics' higher probable upside, analysts clearly believe Summit Therapeutics is more favorable than Enliven Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Enliven Therapeutics
1 Sell rating(s)
1 Hold rating(s)
10 Buy rating(s)
0 Strong Buy rating(s)
2.75
Summit Therapeutics
2 Sell rating(s)
5 Hold rating(s)
10 Buy rating(s)
1 Strong Buy rating(s)
2.56

Enliven Therapeutics is trading at a lower price-to-earnings ratio than Summit Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Enliven TherapeuticsN/AN/A-$103.69M-$1.71N/A
Summit TherapeuticsN/AN/A-$1.08B-$1.07N/A

95.1% of Enliven Therapeutics shares are held by institutional investors. Comparatively, 4.6% of Summit Therapeutics shares are held by institutional investors. 3.0% of Enliven Therapeutics shares are held by company insiders. Comparatively, 81.8% of Summit Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Enliven Therapeutics' return on equity of -16.91% beat Summit Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Enliven TherapeuticsN/A -16.91% -16.52%
Summit Therapeutics N/A -138.82%-117.11%

Summary

Enliven Therapeutics beats Summit Therapeutics on 7 of the 13 factors compared between the two stocks.

How does Enliven Therapeutics compare to Kymera Therapeutics?

Enliven Therapeutics (NASDAQ:ELVN) and Kymera Therapeutics (NASDAQ:KYMR) are both mid-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, profitability, risk, earnings, media sentiment, valuation and institutional ownership.

Enliven Therapeutics has a beta of 0.34, indicating that its share price is 66% less volatile than the broader market. Comparatively, Kymera Therapeutics has a beta of 2.04, indicating that its share price is 104% more volatile than the broader market.

Enliven Therapeutics has a net margin of 0.00% compared to Kymera Therapeutics' net margin of -285.33%. Enliven Therapeutics' return on equity of -16.91% beat Kymera Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Enliven TherapeuticsN/A -16.91% -16.52%
Kymera Therapeutics -285.33%-22.39%-20.48%

Enliven Therapeutics currently has a consensus price target of $75.44, suggesting a potential upside of 62.46%. Kymera Therapeutics has a consensus price target of $139.16, suggesting a potential upside of 20.90%. Given Enliven Therapeutics' higher probable upside, equities analysts clearly believe Enliven Therapeutics is more favorable than Kymera Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Enliven Therapeutics
1 Sell rating(s)
1 Hold rating(s)
10 Buy rating(s)
0 Strong Buy rating(s)
2.75
Kymera Therapeutics
1 Sell rating(s)
2 Hold rating(s)
23 Buy rating(s)
1 Strong Buy rating(s)
2.89

In the previous week, Enliven Therapeutics had 8 more articles in the media than Kymera Therapeutics. MarketBeat recorded 12 mentions for Enliven Therapeutics and 4 mentions for Kymera Therapeutics. Kymera Therapeutics' average media sentiment score of 0.93 beat Enliven Therapeutics' score of 0.82 indicating that Kymera Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Enliven Therapeutics
2 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Kymera Therapeutics
2 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Enliven Therapeutics has higher earnings, but lower revenue than Kymera Therapeutics. Kymera Therapeutics is trading at a lower price-to-earnings ratio than Enliven Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Enliven TherapeuticsN/AN/A-$103.69M-$1.71N/A
Kymera Therapeutics$102.24M96.11-$311.35M-$3.62N/A

95.1% of Enliven Therapeutics shares are held by institutional investors. 3.0% of Enliven Therapeutics shares are held by company insiders. Comparatively, 16.0% of Kymera Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Enliven Therapeutics beats Kymera Therapeutics on 9 of the 16 factors compared between the two stocks.

How does Enliven Therapeutics compare to Halozyme Therapeutics?

Enliven Therapeutics (NASDAQ:ELVN) and Halozyme Therapeutics (NASDAQ:HALO) are both healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, risk, media sentiment, analyst recommendations, profitability, earnings, dividends and valuation.

Halozyme Therapeutics has a net margin of 26.93% compared to Enliven Therapeutics' net margin of 0.00%. Halozyme Therapeutics' return on equity of 751.81% beat Enliven Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Enliven TherapeuticsN/A -16.91% -16.52%
Halozyme Therapeutics 26.93%751.81%23.84%

In the previous week, Halozyme Therapeutics had 14 more articles in the media than Enliven Therapeutics. MarketBeat recorded 26 mentions for Halozyme Therapeutics and 12 mentions for Enliven Therapeutics. Enliven Therapeutics' average media sentiment score of 0.82 beat Halozyme Therapeutics' score of 0.27 indicating that Enliven Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Enliven Therapeutics
2 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Halozyme Therapeutics
8 Very Positive mention(s)
3 Positive mention(s)
8 Neutral mention(s)
2 Negative mention(s)
0 Very Negative mention(s)
Neutral

Halozyme Therapeutics has higher revenue and earnings than Enliven Therapeutics. Enliven Therapeutics is trading at a lower price-to-earnings ratio than Halozyme Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Enliven TherapeuticsN/AN/A-$103.69M-$1.71N/A
Halozyme Therapeutics$1.40B7.46$316.89M$3.9323.24

Enliven Therapeutics has a beta of 0.34, indicating that its share price is 66% less volatile than the broader market. Comparatively, Halozyme Therapeutics has a beta of 0.92, indicating that its share price is 8% less volatile than the broader market.

95.1% of Enliven Therapeutics shares are owned by institutional investors. Comparatively, 97.8% of Halozyme Therapeutics shares are owned by institutional investors. 3.0% of Enliven Therapeutics shares are owned by insiders. Comparatively, 2.5% of Halozyme Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Enliven Therapeutics presently has a consensus price target of $75.44, indicating a potential upside of 62.46%. Halozyme Therapeutics has a consensus price target of $110.17, indicating a potential upside of 20.60%. Given Enliven Therapeutics' stronger consensus rating and higher possible upside, equities analysts plainly believe Enliven Therapeutics is more favorable than Halozyme Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Enliven Therapeutics
1 Sell rating(s)
1 Hold rating(s)
10 Buy rating(s)
0 Strong Buy rating(s)
2.75
Halozyme Therapeutics
1 Sell rating(s)
5 Hold rating(s)
7 Buy rating(s)
0 Strong Buy rating(s)
2.46

Summary

Halozyme Therapeutics beats Enliven Therapeutics on 10 of the 15 factors compared between the two stocks.

How does Enliven Therapeutics compare to BioMarin Pharmaceutical?

BioMarin Pharmaceutical (NASDAQ:BMRN) and Enliven Therapeutics (NASDAQ:ELVN) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, analyst recommendations, earnings, risk, valuation, profitability, institutional ownership and dividends.

In the previous week, BioMarin Pharmaceutical and BioMarin Pharmaceutical both had 12 articles in the media. Enliven Therapeutics' average media sentiment score of 0.82 beat BioMarin Pharmaceutical's score of 0.52 indicating that Enliven Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
BioMarin Pharmaceutical
5 Very Positive mention(s)
2 Positive mention(s)
3 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive
Enliven Therapeutics
2 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

98.7% of BioMarin Pharmaceutical shares are owned by institutional investors. Comparatively, 95.1% of Enliven Therapeutics shares are owned by institutional investors. 0.7% of BioMarin Pharmaceutical shares are owned by insiders. Comparatively, 3.0% of Enliven Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

BioMarin Pharmaceutical has a beta of 0.21, indicating that its share price is 79% less volatile than the broader market. Comparatively, Enliven Therapeutics has a beta of 0.34, indicating that its share price is 66% less volatile than the broader market.

BioMarin Pharmaceutical presently has a consensus price target of $87.22, indicating a potential upside of 44.38%. Enliven Therapeutics has a consensus price target of $75.44, indicating a potential upside of 62.46%. Given Enliven Therapeutics' higher possible upside, analysts clearly believe Enliven Therapeutics is more favorable than BioMarin Pharmaceutical.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
BioMarin Pharmaceutical
1 Sell rating(s)
6 Hold rating(s)
15 Buy rating(s)
3 Strong Buy rating(s)
2.80
Enliven Therapeutics
1 Sell rating(s)
1 Hold rating(s)
10 Buy rating(s)
0 Strong Buy rating(s)
2.75

BioMarin Pharmaceutical has higher revenue and earnings than Enliven Therapeutics. BioMarin Pharmaceutical is trading at a lower price-to-earnings ratio than Enliven Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BioMarin Pharmaceutical$3.66B3.20$348.90M-$0.10N/A
Enliven TherapeuticsN/AN/A-$103.69M-$1.71N/A

Enliven Therapeutics has a net margin of 0.00% compared to BioMarin Pharmaceutical's net margin of -0.52%. BioMarin Pharmaceutical's return on equity of 5.58% beat Enliven Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
BioMarin Pharmaceutical-0.52% 5.58% 3.51%
Enliven Therapeutics N/A -16.91%-16.52%

Summary

BioMarin Pharmaceutical beats Enliven Therapeutics on 9 of the 15 factors compared between the two stocks.

How does Enliven Therapeutics compare to Vaxcyte?

Vaxcyte (NASDAQ:PCVX) and Enliven Therapeutics (NASDAQ:ELVN) are both mid-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, earnings, dividends, risk, valuation, analyst recommendations, institutional ownership and media sentiment.

Enliven Therapeutics is trading at a lower price-to-earnings ratio than Vaxcyte, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
VaxcyteN/AN/A-$766.63M-$8.06N/A
Enliven TherapeuticsN/AN/A-$103.69M-$1.71N/A

Vaxcyte has a beta of 1.31, meaning that its stock price is 31% more volatile than the broader market. Comparatively, Enliven Therapeutics has a beta of 0.34, meaning that its stock price is 66% less volatile than the broader market.

Enliven Therapeutics' return on equity of -16.91% beat Vaxcyte's return on equity.

Company Net Margins Return on Equity Return on Assets
VaxcyteN/A -42.04% -36.82%
Enliven Therapeutics N/A -16.91%-16.52%

In the previous week, Enliven Therapeutics had 8 more articles in the media than Vaxcyte. MarketBeat recorded 12 mentions for Enliven Therapeutics and 4 mentions for Vaxcyte. Enliven Therapeutics' average media sentiment score of 0.82 beat Vaxcyte's score of 0.62 indicating that Enliven Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Vaxcyte
1 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Enliven Therapeutics
2 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Vaxcyte presently has a consensus target price of $117.20, suggesting a potential upside of 111.59%. Enliven Therapeutics has a consensus target price of $75.44, suggesting a potential upside of 62.46%. Given Vaxcyte's higher possible upside, analysts plainly believe Vaxcyte is more favorable than Enliven Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Vaxcyte
1 Sell rating(s)
1 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.63
Enliven Therapeutics
1 Sell rating(s)
1 Hold rating(s)
10 Buy rating(s)
0 Strong Buy rating(s)
2.75

96.8% of Vaxcyte shares are held by institutional investors. Comparatively, 95.1% of Enliven Therapeutics shares are held by institutional investors. 3.3% of Vaxcyte shares are held by company insiders. Comparatively, 3.0% of Enliven Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Enliven Therapeutics beats Vaxcyte on 8 of the 13 factors compared between the two stocks.

Get Enliven Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for ELVN and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ELVN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ELVN vs. The Competition

MetricEnliven TherapeuticsBiotechnology IndustryHealthcare SectorNASDAQ Exchange
Market Cap$3.42B$3.92B$7.44B$10.86B
Dividend YieldN/A3.79%2.51%4.69%
P/E Ratio-27.1623.0732.5628.72
Price / SalesN/A15.358.005.34
Price / CashN/A21.9220.2520.77
Price / Book3.904.124.343.51
Net Income-$103.69M-$24.08M$3.51B$394.12M
7 Day Performance-4.84%-9.85%-8.07%-8.97%
1 Month Performance10.76%-12.77%-10.29%-11.61%
1 Year Performance113.52%-7.99%-4.70%-11.21%

Enliven Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ELVN
Enliven Therapeutics
2.616 of 5 stars
$46.44
+0.1%
$75.44
+62.5%
+113.5%$3.42BN/AN/A65
SMMT
Summit Therapeutics
2.4074 of 5 stars
$17.83
-0.1%
$28.61
+60.4%
-38.5%$14.27BN/AN/A265
KYMR
Kymera Therapeutics
2.4372 of 5 stars
$136.64
-1.6%
$139.16
+1.8%
+74.3%$11.85B$39.21MN/A285
HALO
Halozyme Therapeutics
4.5395 of 5 stars
$102.98
+0.1%
$106.73
+3.6%
+29.9%$11.73B$1.40B18.48423
BMRN
BioMarin Pharmaceutical
4.2199 of 5 stars
$57.13
-0.1%
$87.91
+53.9%
+10.5%$11.08B$3.22B32.123,221

Related Companies and Tools


This page (NASDAQ:ELVN) was last updated on 11/22/2026 by MarketBeat.com Staff.
From Our Partners